Newswire (Published: Monday, March 13, 2017, 12:01:00 AM CDT, Received: Thursday, March 9, 2017, 4:54:06 PM CST)

Word Count: 508

Brigham and Women's Hospital Reports Findings in Prostate Cancer (Duration of the anti-androgen in men undergoing 6 months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death)

By a News Reporter-Staff News Editor at Clinical Trials Week -- Data detailed on Oncology - Prostate Cancer have been presented. According to news originating from Boston, Massachusetts, by NewsRx correspondents, research stated, "Whether adding a first-generation anti-androgen (AA) to a luteinizing hormone-releasing hormone agonist in the radiotherapeutic management of unfavorable-risk prostate cancer (PC) reduces the risk of all-cause and PC-specific mortality (ACM and PCSM) among men within differing comorbidity subgroups is unknown. Between 1995 and 2001, 206 men with unfavorable-risk PC were enrolled in a randomized trial comparing radiation with or without 6 months of androgen-deprivation therapy (ADT)."

Our news journalists obtained a quote from the research from Brigham and Women's Hospital, "Partial AA use (median: 4.2 months) occurred in 29 of the 102 men randomized to ADT. Cox, and Fine and Gray's regressions were used to evaluate the impact of full versus partial AA use on PCSM and ACM-risk within comorbidity subgroups. After a median follow-up of 16.62 years, 156 men died. In men with moderate to severe comorbidity increasing death was observed as treatment transitioned from no to partial to full ADT (p=0.02) with an increased ACM-risk with full versus partial AA use (adjusted hazard ratio (AHR), 2.25 (95% confidence interval (CI), 0.94-5.41); p=0.07); whereas only 1 and no PC deaths occurred in men receiving a partial versus full AA course, respectively. Among men with no or minimal comorbidity there was no decrease in ACM (AHR, 0.97 (95% CI, 0.49-1.91); p=0.92) or PCSM-risk (AHR 0.39 (95% CI 0.07-52.18); p=0.28) in comparing full versus partial AA use."

According to the news editors, the research concluded: "Increasing AA use by 2 months does not appear to impact survival in men with localized unfavorable-risk PC and no or minimal comorbidity, but may shorten survival in men with moderate to severe comorbidity, raising concern regarding in whom and for how long the AA should be prescribed."

For more information on this research see: Duration of the anti-androgen in men undergoing 6 months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death. Prostate Cancer and Prostatic Diseases, 2016;20(1):79-84. (Nature Publishing Group -; Prostate Cancer and Prostatic Diseases -

The news correspondents report that additional information may be obtained from N.N. Sanford, Dept. of Radiation Oncology, Brigham and Women's Hospital, Boston, MA, United States. Additional authors for this research include M.H. Chen, M. Loffredo, A. Renshaw, P.W. Kantoff and A.V D'Amico (see also Oncology - Prostate Cancer).

Keywords for this news article include: Boston, Hormones, Oncology, Androgens, Massachusetts, United States, Prostate Cancer, Radiation Therapy, Drugs and Therapies, Prostatic Neoplasms, North and Central America.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC


The Brigham and Women's Hospital Inc


Central America
North America
United States


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Medical and Pharmaceutical Regulation
            Drug and Device Approval Process
      Treatments and Therapies
            Medicinal Drugs